203 related articles for article (PubMed ID: 21633294)
1. Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.
Haga SB; O'Daniel JM; Tindall GM; Lipkus IR; Agans R
Genet Med; 2011 Aug; 13(8):723-8. PubMed ID: 21633294
[TBL] [Abstract][Full Text] [Related]
2. Public perspectives about pharmacogenetic testing and managing ancillary findings.
Haga SB; Tindall G; O'Daniel JM
Genet Test Mol Biomarkers; 2012 Mar; 16(3):193-7. PubMed ID: 22047505
[TBL] [Abstract][Full Text] [Related]
3. Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results.
Haga SB; Kawamoto K; Agans R; Ginsburg GS
Genet Med; 2011 Oct; 13(10):887-90. PubMed ID: 21673581
[TBL] [Abstract][Full Text] [Related]
4. Survey of US public attitudes toward pharmacogenetic testing.
Haga SB; O'Daniel JM; Tindall GM; Lipkus IR; Agans R
Pharmacogenomics J; 2012 Jun; 12(3):197-204. PubMed ID: 21321582
[TBL] [Abstract][Full Text] [Related]
5. Professional perspectives about pharmacogenetic testing and managing ancillary findings.
Haga SB; Tindall G; O'Daniel JM
Genet Test Mol Biomarkers; 2012 Jan; 16(1):21-4. PubMed ID: 21770772
[TBL] [Abstract][Full Text] [Related]
6. Physicians' opinions following pharmacogenetic testing for psychotropic medication.
Walden LM; Brandl EJ; Changasi A; Sturgess JE; Soibel A; Notario JF; Cheema S; Braganza N; Marshe VS; Freeman N; Tiwari AK; Kennedy JL; Müller DJ
Psychiatry Res; 2015 Oct; 229(3):913-8. PubMed ID: 26298505
[TBL] [Abstract][Full Text] [Related]
7. Positive perception of pharmacogenetic testing for psychotropic medications.
Lanktree MB; Zai G; Vanderbeek LE; Giuffra DE; Smithson DS; Kipp LB; Dalseg TR; Speechley M; Kennedy JL
Hum Psychopharmacol; 2014 May; 29(3):287-91. PubMed ID: 24604560
[TBL] [Abstract][Full Text] [Related]
8. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
[TBL] [Abstract][Full Text] [Related]
9. How interested is the public in genetic testing for colon cancer susceptibility? Report of a cross-sectional population survey.
Graham ID; Logan DM; Hughes-Benzie R; Evans WK; Perras H; McAuley LM; Laupacis A; Stern H
Cancer Prev Control; 1998 Aug; 2(4):167-72. PubMed ID: 10093629
[TBL] [Abstract][Full Text] [Related]
10. Ancillary risk information and pharmacogenetic tests: social and policy implications.
Henrikson NB; Burke W; Veenstra DL
Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
[TBL] [Abstract][Full Text] [Related]
11. Public Attitudes, Interests, and Concerns Regarding Polygenic Embryo Screening.
Furrer RA; Barlevy D; Pereira S; Carmi S; Lencz T; Lázaro-Muñoz G
JAMA Netw Open; 2024 May; 7(5):e2410832. PubMed ID: 38743425
[TBL] [Abstract][Full Text] [Related]
12. Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs.
McDermott JH; Sharma V; Newman WG; Wilson P; Payne K; Wright S
Br J Clin Pharmacol; 2024 Jul; 90(7):1699-1710. PubMed ID: 38616172
[TBL] [Abstract][Full Text] [Related]
13. Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing.
Haga SB; O'Daniel JM; Tindall GM; Mills R; Lipkus IM; Agans R
Clin Genet; 2012 Aug; 82(2):115-20. PubMed ID: 22283474
[TBL] [Abstract][Full Text] [Related]
14. Assessment of healthcare professionals' knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt.
Nagy M; Lynch M; Kamal S; Mohamed S; Hadad A; Abouelnaga S; Aquilante CL
Per Med; 2020 Jul; 17(4):251-260. PubMed ID: 32589096
[No Abstract] [Full Text] [Related]
15. Primary care physicians' knowledge of and experience with pharmacogenetic testing.
Haga SB; Burke W; Ginsburg GS; Mills R; Agans R
Clin Genet; 2012 Oct; 82(4):388-94. PubMed ID: 22698141
[TBL] [Abstract][Full Text] [Related]
16. Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report.
Drelles K; Pilarski R; Manickam K; Shoben AB; Toland AE
Public Health Genomics; 2021; 24(1-2):26-32. PubMed ID: 33445171
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing uptake of pharmacogenetic testing in a diverse patient population.
O'Daniel J; Lucas J; Deverka P; Ermentrout D; Silvey G; Lobach DF; Haga SB
Public Health Genomics; 2010; 13(1):48-54. PubMed ID: 19407441
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic testing: not as simple as it seems.
Haga SB; Burke W
Genet Med; 2008 Jun; 10(6):391-5. PubMed ID: 18496219
[TBL] [Abstract][Full Text] [Related]
19. Patients' and physicians' perspectives on pharmacogenetic testing.
Rogausch A; Prause D; Schallenberg A; Brockmöller J; Himmel W
Pharmacogenomics; 2006 Jan; 7(1):49-59. PubMed ID: 16354124
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
